2. Cell Cycle/DNA Damage Epigenetics Apoptosis
  3. HDAC Apoptosis
  4. Purinostat mesylate

Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia.

For research use only. We do not sell to patients.

Purinostat mesylate Chemical Structure

Purinostat mesylate Chemical Structure

CAS No. : 2650188-32-0

Size Price Stock
5 mg USD 560 Ask For Quote & Lead Time
10 mg USD 900 Ask For Quote & Lead Time
25 mg USD 1875 Ask For Quote & Lead Time
50 mg USD 3000 Ask For Quote & Lead Time
100 mg USD 4800 Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Purinostat mesylate Related Antibodies

Top Publications Citing Use of Products

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia[1].

IC50 & Target

HDAC1

0.81 nM (IC50)

HDAC10

1.1 nM (IC50)

HDAC2

1.4 nM (IC50)

HDAC3

1.7 nM (IC50)

HDAC8

3.8 nM (IC50)

HDAC6

11.5 nM (IC50)

HDAC5

426 nM (IC50)

HDAC7

590 nM (IC50)

HDAC9

622 nM (IC50)

HDAC4

1072 nM (IC50)

HDAC11

3349 nM (IC50)

In Vitro

Purinostat mesylate (1-10 μM) inhibits HDAC1, 2, 3 and 8 with IC50s of 0.81, 1.4, 1.7 and 3.8 nM, inhibits HDAC6 and 10 with IC50s of 11.5 and 1.1 nM, and inhibits HDAC4, 5, 7, 9 and 11 with IC50s of 1072, 426, 690, 622 and 3348 nM, respectively[1].
Purinostat mesylate (0-60 nM; 24 h) induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purinostat mesylate Related Antibodies

Cell Proliferation Assay[1]

Cell Line: LAMA84 and 188 BL-2 cell lines
Concentration: 0-80 nM
Incubation Time: 24, 48 and 72 hours
Result: Significantly inhibited cell proliferation of LAMA84 and 188 BL-2 cells.

Apoptosis Analysis[1]

Cell Line: LAMA84 and 188 BL-2 cell lines
Concentration: 0-60 nM
Incubation Time: 24 hours
Result: Induced apoptosis of LAMA84 and 188 BL-2 cells.

Cell Cycle Analysis[1]

Cell Line: LAMA84 and 188 BL-2 cell lines
Concentration: 0-40 nM
Incubation Time: 24 hours
Result: Dose-dependently blocked cell cycle progression at G0/G1 phase.

Western Blot Analysis[1]

Cell Line: LAMA84 and 188 BL-2 cell lines
Concentration: 0-40 nM
Incubation Time: 24 hours
Result: Dose-dependently increased the 191 levels of Ac-H3 and Ac-H4, and decreased HSP90.
In Vivo

Purinostat mesylate (5-10 mg/kg; i.p. three times a week for 5 weeks) effectively suppresses leukemia progression in vivo[1].
Purinostat mesylate (5-10 mg/kg; i.v. three times a week for 8 weeks) shows potently anti-leukemia effects in BCR-ABL(T315I)-induced primary B-ALL mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Non-irradiated C57BL/6 recipient mice with BL-2 cells injection[1]
Dosage: 5 and 10 mg/kg
Administration: Intraperitoneal injection; 5-10 mg/kg three times a week; for five weeks
Result: Significantly prolonged the overall survival rate and suppressed leukemia progression of mice, and no tumor cell was detected after stopped treatment.
Animal Model: Non-irradiated C57BL/6 recipient mice with BL-2 secondary transplantation[1]
Dosage: 10 mg/kg
Administration: Intravenous injection; 10 mg/kg three times a week
Result: Completely eliminated GFP+B220+ cells in spleens on day 3 with two times treatment and this complete inhibition was maintained for 26 days duration of treatment.
Animal Model: B-ALL mouse with BCR-ABL(T315I)-induced leukemia[1]
Dosage: 5 and 10 mg/kg
Administration: Intravenous injection; 5 and 10 mg/kg three times a week; for 8 weeks
Result: Significantly prolonged survival rate of BCR-ABL(T315I)-induced B-ALL mice. Survived all mice after treatment for 42 days.
Molecular Weight

586.62

Formula

C24H30N10O6S
CAS No.
SMILES

O=C(C1=CN=C(N(CC2=NC3=C(N4CCOCC4)N=C(C5=CC=C(N)C=C5)N=C3N2C)C)N=C1)NO.O=S(O)(C)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Purinostat mesylate Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Purinostat2650188-32-0HDACApoptosisHistone deacetylasesselectiveBCR-ABLB-cell acutelymphoblastic leukemiamouse modelsuperior efficiencyLAMA84188 BL-2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Purinostat mesylate
Cat. No.:
HY-150109
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.